期刊文献+

肾上腺脑白质营养不良临床及实验室随访研究 被引量:4

Follow-up study on clinical features and laboratory data of adrenoleukodystrophy
下载PDF
导出
摘要 目的:研究X-连锁肾上腺脑白质营养不良的临床、生化改变及治疗情况。方法:对疑诊患儿,结合临床症状、实验室检查等确诊,给予洛伐他汀治疗。就临床症状体征,药物不良反应,实验室指标等进行动态随诊观察。结果:应用洛伐他汀治疗,能使肾上腺脑白质营养不良患儿血极长链脂肪酸水平明显下降甚至趋于正常水平,但对已出现的神经系统症状无改善作用,对尚未出现的神经系统症状有延缓出现的可能性。结论:早诊断、早治疗是减缓肾上腺脑白质营养不良患儿神经系统症状出现的有效方法。 Objective To investigate the typical clinical manifestations, biochemical change and treatment of X-linked adrenoleukodystrophy. Methods The clinical situation, adverse reactions of lovastatin and laboratory data of adrenoleukodystrophy patients treated with lovastatin were reviewed retrospectively. Results When treaded with lovastatin, the very long chain fatty acids level of X- linked adrenoleukodystrophy patients in their plasma showed lowered whereas showed unchanged in symptom of central nervous system, which reduced the possibility that adrenoleukodystrophy patients without symptom of central nervous system appeared central nervous system abnormally. Conclusion The modus operandi to slow down the appearance of symptom of nervous system of adrenoleukodystrophy patients is to diagnose and treat in their early courses.
出处 《实用诊断与治疗杂志》 2007年第9期641-643,共3页 Journal of Practical Diagnosis and Therapy
关键词 X-连锁肾上腺脑白质营养不良 生化改变 治疗 X-linked adrenoleukodystrophy laboratory data treatment
  • 相关文献

参考文献10

  • 1Moser H W.Adrenoleukodystrophy:phenotype,genetics,pathogenesis and therapy[J].Brain,1997,120 (Pt8):1485-1508.
  • 2Moser H W,Moser A B,Frayer K K,et al.Adrenoleukodystrophy:Increased plasma content of saturated very long chain fatty acids[J].Neurology,1981,31(10):1241-1249.
  • 3陈光华 张美德 何坚娘.肾上腺脑白质营养不良(病例及文献复习).中国神经精神疾病杂志,1987,13:227-227.
  • 4Moser A B,Kreiter N,Bezman L,et al.Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls[J].AnnNeurol,1999,45(1):100-110.
  • 5Bezman L,Moser H W.Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes[J].AnnNeurol,2001,49(4):512-517.
  • 6Dubois-Dalcq M,Feigenbaum V,Aubourg P.The neurobiology of X-link adrenoleukodystrophy,a demyelinating peroxisomal disorder[J].Trends Neurosci,1999,22(1):4-12.
  • 7Pahan K,Khan M,Singh I,et al.Therapy for X-linked adrenoleukodystrophy:normalization of very long chain fatty acids and Inhibition of induction of cytokines by Camp[J].J Lipid Res,1998,39(5):1091-1100.
  • 8Wichers M,Kohler W,Brennemann W,et al.X-linked adrenomyeloneuropathy associated with 14 novel ALD-gene mutation:no correlation between type of mutation and age of onset[J].Hum Genet,1999,105(2):116-119.
  • 9Fourcade S,Savary S,Albet S,et al.Fibrate induction of the adrenoleukodystrophy related gene (ABCD2):promoter analysis and role of the peroxisome proliferators activated receptor PPARa[J].Eur J Biochem,2001,45(268):3490-3500.
  • 10Pai G S,Khan M,Barbosa E,et al.Lovastatin therapy for adrenoleukodystrophy and adrenomyeoneuroparthy:clinical and biochemical observations on 12 patients[J].Mol Genet Metab,2000,69(4):312-322.

同被引文献76

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部